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charge. Scenario 1 represented a valuation of inhaled ver-
sus intravenous induction and scenario 2 represented a
valuation of inhaled versus intravenous maintenance. An
open-ended question was directed to test understanding
of the exercise, and thus validity of the valuation given. A
thematic framework approach was used to analyze these
qualitative data. A second researcher checked the consis-
tency of the coding of the themes in a sub-sample of the
statements (inter-rater reliability).
RESULTS: 260 (81%) parents/guardians and 907 (85%)
adults recruited onto the RCT were telephoned around
day seven. 88% and 85% of parents/guardians’ and
adults’ responses were classed as valid, respectively. 69%
of adults preferred an injection for induction (mean CV:
£237, SD: £370) and 31% preferred a mask (mean CV:
£144, SD: £110, p  .05). 97% of adults selected the sce-
nario with a lower nausea and vomiting rate (mean CV:
£192, SD: £149). 57% of parent/guardians preferred a
mask for induction (mean CV: £255, SD: £259) and 43%
preferred an injection (mean CV: £221, SD: £177, ns).
99% of parents/guardians selected the scenario with a
lower nausea and vomiting rate (mean CV: £238, SD:
£194).
CONCLUSION: Contingent valuation was used success-
fully in this prospective study. Telephone interviewing
produced a high response rate and respondent under-
standing of the exercise was high.
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OBJECTIVE: Quality of life (QoL) is a key parameter in
describing the impact of Systemic Lupus Erythematosus
(SLE). The reliability and validity of the Hungarian ver-
sion of the SLEQoL were assessed with the intention of
using it in clinical and health economic trials and burden-
of-disease studies in Hungary.
METHODS: Data were collected through a postal survey
of patients with SLE. Participants completed the SLEQoL
and Nottingham Health Profile (NHP) on two occasions,
two weeks apart. Test-retest reliability was assessed by
correlating SLEQoL scores at the two time points. Inter-
nal consistency was assessed using Cronbach’s alpha co-
efficients. Evidence of construct validity was gained by
correlating SLEQoL scores with NHP section scores and
by testing whether the measure was able to distinguish
groups that differed according to self-perceived severity
of condition.
RESULTS: Fifty-three patients participated in the survey.
Mean age of the sample was 39.9 years (SD  12.2), 49
patients (92.5%) were female and mean disease duration
was 12.0 years (SD  8.2). Test-retest reliability for pa-
tients who had no change in their condition between ad-
ministrations was 0.94. Cronbach’s alpha coefficients
were 0.90 and 0.93 at times 1 and 2 respectively. The
highest correlation was observed with the emotional re-
actions section of NHP and the lowest with pain and
sleep disturbance. Patients who perceived the severity of
their condition to be moderate or quite severe obtained
higher SLEQoL scores (indicating poorer QoL) than
those who perceived their condition to be mild (p  .05).
CONCLUSION: The Hungarian SLEQoL was shown to
have good test-retest reliability, indicating that it pro-
duces little random measurement error. Evidence of va-
lidity was also good. The results provide preliminary evi-
dence that the instrument will be able to detect changes
in QoL occurring in routine clinical practice or in clinical
trials or studies.
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OBJECTIVES: To date, surgical interventions in people
with haemophilia and high-titre, high-responding inhibi-
tors have been largely restricted to life-threatening situa-
tions. This is to the detriment of patients who would ben-
efit from surgery in terms of reduced pain, a reduction in
the frequency of regular bleeding episodes and improved
quality of life. However, with the development of recom-
binant FVIIa (rFVIIa: Novo Nordisk Ltd) elective surgery
such as joint replacement can be carried out safely with
effective haemostasis. This study examines the cost-con-
sequences of surgical intervention in this patient group
over time, to establish an estimate of the net cost of sur-
gery.
METHODS: A modeling framework has been used to es-
timate costs associated with haemostasis (rFVIIa treat-
ment) in patients for nine surgical procedures, and to
consider the cost-consequences of the intervention over a
five-year time horizon. Key parameters in the model have
been obtained from available literature (i.e. assumption
of reduction in bleeding episodes) and expert opinion
from a leading Haemophilia Comprehensive Care Centre
(i.e., protocols for haemostasis required during ortho-
paedic surgery, physiotherapy and rehabilitation).
RESULTS: For a typical person with haemophilia with
inhibitors, weighing 75kg, experiencing one regular bleed
per month in the affected joint, the costs for haemostasis
associated with total hip replacement are an estimated
£322,911. However, the net cost, when considering the
reduced costs of treatment for regular minor bleeds over
the following 5 years, are £298,401 (cost-saving) when
treating first line with rFVIIa.
CONCLUSIONS: In addition to improved quality of life,
orthopaedic surgery in people with haemophilia and in-
hibitors may be cost-saving when the reduction in regular
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minor bleeds is taken into account, and the subsequent
cost consequences over time offset the surgical costs.
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OBJECTIVES: Emergency liver transplantation repre-
sents the only effective and recognized therapy for fulmi-
nant hepatic failure (FHF). However, many patients die
while waiting for a donor liver. Bioartificial liver devices
such as the Extracorporeal Liver Assist Device (ELAD)
could allow for sufficient support until a donor liver be-
comes available or until the patient’s own liver can re-
cover. The objective of this study was to assess the cost-
effectiveness of ELAD in FHF patients.
METHODS: We performed a cost-effectiveness analysis
from a payer perspective using clinical data from 19 pa-
tients who received either ELAD or usual care in a Phase
II randomized clinical trial. A statistically significant im-
provement in bridging to transplant with the use of
ELAD was found, with 67% ELAD patients surviving 30
days, compared to 43% of patients in the usual care
group. A decision-analytic model was used to determine
the incremental cost per additional year of life gained
with ELAD versus usual care. Costs were derived from
liver transplant literature.
RESULTS: The incremental cost per additional year of
life gained for ELAD compared with usual care ranged
from $49,200 to $71,500. Among those patients requir-
ing liver transplant, the cost per additional year of life
gained was $52,600 compared to individuals not receiv-
ing a transplant. The model was sensitive to assumptions
regarding the cost of ELAD and the proportion of pa-
tients successfully bridged to transplant.
CONCLUSIONS: ELAD bioartificial liver device may of-
fer both survival and economic benefits to FHF patients.
ELAD appears to be a reasonable and cost-effective alter-
native to usual care in the treatment of FHF. In addition
to its value as a bridge to transplant, ELAD may offer
even more health and cost benefits as a bridge to recov-
ery. Future studies will continue to examine this effect
across larger populations.
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OBJECTIVE: To perform economic evaluations both of
cost-effectiveness (C/E) and cost-utility (C/U) analysis of
erectile dysfunction treatments, sildenafil and intracav-
ernous alprostadil, depending on whether they are pre-
scribed in primary (PC) or specialized (SC) care.
METHODS: The costs include diagnosis, treatment and
clinical follow-up, have been obtained from Spanish offi-
cial Administration and Hospitals data. The cost of the
treatment was the wholesale price in year 2000. Utility
units were assessed using time trade-off and efficacy rates
obtained from the scientific literature.
RESULTS: The annual costs of the treatments for four
monthly drug administrations, vary between €421,02
(sildenafil in PC); €608,42 (sildenafil in SC) and €715,28
(alprostadil IC) for the first year and €370,89 (sildenafil
PC), €404,67 (sildenafil SC) and €465,92 (alprostadil)
for each of the following years. The C/E and C/U values
lie between €568,18 and €3,465.19, respectively for
sildenafil in PC and €821,07 and €5.007,54 respectively
for sildenafil in PC for the first year of treatment. For al-
prostadil, the values during the first year are €1.027,71
(C/E) and €5.431,5 (C/U). For the following years they
are €500,53 (C/E) and €3053,60 (C/U) for sildenafil in PC,
€546,11 (C/E) and €3330,60 (C/U) for sildenafil in SC
and €669,43 (C/E) and €3537,76 (C/U) for alprostadil.
CONCLUSIONS: Treatment with sildenafil is cheaper
than with alprostadil. Sildenafil has a better pharmaco-
economic profile than alprostadil, both in terms of C/U
and C/E analyses. Sildenafil is the best therapeutic option
in terms of C/E and C/U ratios for the treatment of erec-
tile dysfunction when it is prescribed in primary care.
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OBJECTIVE: To develop a generalizable, responsive and
sensitive self-administered instrument by combining dis-
ease-specific and preference-based approaches in an ED-
specific HRQL instrument.
METHODS: Literature review provided structure for ex-
pert panel discussion. Consensus regarding content pro-
duced eight domains and five levels within each domain
describing a continuum of dysfunction-function. This
content formed the foundation for a preference-based
self-administration HRQL instrument, consisting of two
visual analog scales (VAS). Scale 1 allows the rating of
the patient’s self-state along with three ‘marker’ health
